Extending the P4P agenda, part 2: how Medicare can reduce waste and improve the care of the chronically ill.

Extending the Pay-for-Performance Agenda: Part One How Medicare Can Improve the Quality of Patient Decision Making and Reduce Unnecessary Care A Synopsis

Differences in Receipt of Three Preventive Health Care Services by Race/Ethnicity in Medicare Advantage Plans: Tracking the Impact of Pay for Performance, 2010 and 2013

INTRODUCTION In 2012, the Centers for Medicare and Medicaid Services (CMS) introduced the Quality Bonus Payment Demonstration, a pay-for-performance (P4P) program, into Medicare Advantage plans. Previous studies documented racial/ethnic disparities in receipt of care among participants in these plans. The objective of this study was to determine whether P4P incentives have affected these dispar...

Pay-for-Performance Initiatives

BACKGROUND: Improving the quality of care provided to beneficiaries while reining in costs, is a key goal for Medicare programs. The emerging payfor-performance (P4P) movement is a reimbursement strategy that provides incentives to improve the overall quality care provided to patients, which can lead to improved clinical outcomes and reduced health care utilization and costs. OBJECTIVE: To revi...

Comparative Study of the Relationship between Spiritual Well-being and Sense of Coherence in Mothers with Chronically Ill Children in Kerman, Iran, in 2016

This study aimed to investigate the relationship between spiritual well-being and sense of coherence in the mothers having children with chronic diseases. To this end, a controlled cross-sectional evaluation was conducted on 300 mothers, divided into two groups of 150 cases with healthy and chronically ill children in the city of Kerman, Iran, in 2016. The data were collected using the Platosin...

Medicare challenges and solutions--reimbursement issues in treating the patient with colorectal cancer.

BACKGROUND Medicare covers costs far more than 50% of all cancer patients, and most private payers follow Medicare's lead on coverage and benefits for cancer care. Medicare and private payers are legally required by federal statute to cover anticancer chemotherapeutic products based on U.S. Food and drug administration-approved labeling and indicate how off-label uses are covered. OBJECTIVE T...